BXTAccelyon

What BXTAccelyon does

BXTAccelyon Limited is a UK-based private healthcare distributor founded in 2013 that specialises in LDR (Low Dose Rate) brachytherapy for localised prostate cancer. The company supplies Iodine-125 radioactive seeds (typically 80-120 per procedure, permanently implanted into the prostate gland) and ancillary devices to radiotherapy and urology departments, primarily serving hospitals and cancer treatment centres. Its core technology stack centres on 4D Brachytherapy™, a real-time stranded-and-loose seed implantation technique, complemented by WebBXT, a web-based treatment planning platform. Through exclusive distribution agreements, the company also distributes PrecisionPoint™, a single-use transperineal biopsy access device, outside North America and globally offers MRI PRO, a CME-accredited subscription e-learning platform with 300 histologically verified prostate MRI cases.

The company generates revenue primarily through B2B hardware sales of brachytherapy seeds, delivery needles, and medical devices, supplemented by recurring subscription revenue from MRI PRO training. It serves 415 hospitals across 13 countries including the UK, Ireland, Belgium, Germany, Greece, Iceland, the Netherlands, Australia, and New Zealand, with named customers spanning major NHS trusts (Royal Marsden, University Hospital Southampton, Edinburgh Cancer Centre) and private centres such as Galway Clinic. GTM is built on enterprise field sales to radiotherapy departments supported by channel partner relationships and reinforced through professional education, conferences (BAUS, BAUN, EAUN), and alliances with Prostate Cancer UK, BAUS, and the Royal Society of Medicine around the TRexit initiative to phase out transrectal biopsies. The company is led by Managing Director Saheed Rashid, holds a 2020 MedTech Breakthrough Award, and has supported 30 clinical trials and studies documenting >90% disease-free survival at 10+ years and a claimed No. 1 post-treatment quality-of-life ranking versus alternative prostate cancer treatments.

Name

BXTAccelyon

Legal name

BXTAccelyon Limited

Website

https://bxta.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

BXTAccelyon is a UK-based healthcare distributor that supplies Iodine-125 brachytherapy seeds, the PrecisionPoint™ biopsy device, and the MRI PRO training platform to hospitals and cancer treatment centres across 13 countries for the treatment of localised prostate cancer.

Ownership category

akta.pro rank

Product category

Radiation Oncology Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Brachytherapy seeds
• Prostate cancer treatment
• Medical device distribution
• Radiation oncology products
• Transperineal biopsy devices

Headquarters

HQ city

Burnham

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Brachytherapy Seeds and Products: Sale of Iodine-125 radioactive seeds, ancillary products, and medical devices for brachytherapy procedures. Products include stranded and loose seeds, delivery needles, and related brachytherapy equipment.
2. Medical Devices and Equipment: Distribution of proprietary medical devices including PrecisionPoint™ transperineal access system for prostate biopsy procedures.
3. Training and Education Subscriptions: Subscription-based e-learning platform for prostate MRI diagnostics (MRI PRO) providing CME-accredited training for healthcare professionals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

BXTAccelyon supplies Low Dose Rate (LDR) brachytherapy seeds made of Iodine-125, along with proprietary medical devices and educational platforms, to hospitals and cancer treatment centres worldwide. Its portfolio includes the PrecisionPoint™ transperineal biopsy access system, 4D Brachytherapy™ real-time implantation technique, WebBXT treatment planning software, and MRI PRO e-learning subscription for prostate MRI diagnostics. The company serves as a leading distribution and clinical partner for prostate cancer diagnosis and treatment across 13 countries.

Product overview

BXTAccelyon offers a portfolio of prostate cancer treatment products and services centered on LDR (Low Dose Rate) brachytherapy. The core offering is the Iodine-125 brachytherapy seed system for permanent prostate implantation, enhanced by 4D Brachytherapy™ technology for real-time treatment delivery. The company also provides PrecisionPoint™, a transperineal biopsy access device, and WebBXT, a web-based treatment planning platform. Supporting these clinical products is MRI PRO, an online educational subscription platform for prostate MRI interpretation training. The portfolio is rounded out by customer services including supply chain logistics to hospitals in 13 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• LDR Brachytherapy (Iodine-125 Seeds) Low Dose Rate brachytherapy is a targeted form of internal radiotherapy for prostate cancer using tiny radioactive Iodine-125 seeds about the size of a grain of rice, inserted permanently into the prostate gland. Between 80-120 seeds are used depending on prostate and tumour size, emitting radiation that targets the tumour while minimising damage to surrounding healthy tissue.
• 4D Brachytherapy™ A novel, real-time prostate brachytherapy technique using stranded and loose seeds, representing an advancement in LDR brachytherapy with enhanced precision and treatment planning capabilities for urologists and radiation oncologists.
• PrecisionPoint™ A single-use transperineal access system that enables Local Anaesthetic Transperineal (LATP) prostate biopsies. The device allows free-hand operation in local anaesthetic settings, decreasing infection risk compared to transrectal approaches while enabling systematic sampling of all prostate regions.
• MRI PRO An online self-learning subscription platform for prostate MRI diagnostics featuring 300 histologically verified prostate MRI cases diagnosed according to PIRADS v.2 specifications using 3T magnets. Users submit answers for PIRADS scores, index lesion locations, and staging information, receiving immediate feedback including biopsy reports.
• WebBXT A web-based platform for brachytherapy treatment planning and data management, supporting healthcare professionals in real-time prostate brachytherapy procedures.

Quantifiable outcome

• 180,000+ patients treated globally
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• MRI PROcoreTechnology or Integration · 1 January 2019Global distribution partnership for MRI PRO, an online self-learning tool for prostate MRI diagnostics. BXTA distributes this CME-accredited e-learning platform that provides 300 histologically verified prostate MRI cases for healthcare professional training. The platform is accredited by EACCME, AMA, Royal Australasian College of Surgeons, and Royal Australian and New Zealand College of Radiologists.
• PrecisionPoint™coreOEM/ Whitelabel/ Licensing Partner · 1 January 2017Sole distributor outside North America for PrecisionPoint™ transperineal access system, a medical device enabling local anaesthetic transperineal prostate biopsy (LATP). The partnership addresses the TRexit initiative to replace transrectal biopsies with safer transperineal approaches.
• Hitachi Medical SystemsminorStrategic or Co-development PartnerPartnership to support the TRexit initiative, working together to promote the replacement of transrectal prostate biopsy with transperineal approaches using PrecisionPoint™.
• British Association of Urological Surgeons (BAUS)minorStrategic or Co-development PartnerProfessional association partnership supporting the TRexit initiative and promoting best practices in prostate cancer diagnosis.
• Prostate Cancer UKminorStrategic or Co-development PartnerCharity partnership supporting prostate cancer awareness and patient education initiatives.
• British Association of Urological NursesminorStrategic or Co-development PartnerProfessional nursing association partnership supporting education and training for urology nurses in prostate cancer care.
• Royal Society of MedicineminorStrategic or Co-development PartnerMedical education partnership supporting professional development and knowledge sharing in prostate cancer treatment.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Lantheus Holdings: Lantheus is a radiopharmaceutical company producing diagnostic and therapeutic nuclear medicine products. It is comparable as a broader radiopharmaceutical/radiation-based prostate cancer player with greater scale than BXTA.
• Accuray: Accuray develops robotic radiosurgery and SBRT systems (CyberKnife, TomoTherapy) that compete with LDR brachytherapy as alternative prostate cancer treatments. It targets the same radiation oncology customer base as BXTA, particularly in European cancer centres.
• Elekta: Elekta provides linear accelerators, brachytherapy afterloaders (Flexitron), and oncology software used by the same hospital radiotherapy departments BXTA serves. It is a broad incumbent in radiation oncology rather than a seed specialist, but competes for clinical workflow ownership.
• Bayer (Radiopharmaceuticals): Bayer operates in radiopharmaceuticals (e.g., Xofigo/radium-223) and broader oncology. While not a direct seed competitor, Bayer's scale and prostate cancer footprint position it as an adjacent incumbent competing for urology/oncology hospital budgets.
• Varian Medical Systems (Siemens Healthineers): Varian (now part of Siemens Healthineers) is a global leader in radiation oncology hardware and software, including brachytherapy afterloaders and treatment planning. It overlaps with BXTA at the hospital procurement level and competes for the radiotherapy department budget.
• Becton, Dickinson and Company (BD): BD (via C.R. Bard) has historically offered brachytherapy products and supplies a wide range of urology and oncology devices. It overlaps with BXTA at the hospital procurement layer, especially in biopsy and prostate procedure consumables.

Direct peers

• IsoRay Medical: IsoRay produces Cesium-131 and Iodine-125 brachytherapy seeds for prostate, brain, and other cancers. It is a direct competitor in the LDR brachytherapy seed market that BXTA serves and overlaps in target customers (radiation oncologists and treatment centres).
• Eckert & Ziegler BEBIG: Eckert & Ziegler BEBIG manufactures HDR and LDR brachytherapy seeds, afterloaders, and ocular applicators. It directly competes with BXTA in prostate brachytherapy seeds across European and international markets.
• Theragenics Corporation: Theragenics manufactures and distributes brachytherapy seeds (including iodine-125 and palladium-103) for prostate and other cancers. It directly competes with BXTA's core Iodine-125 seed business and shares the same hospital channel in radiation oncology.

Emerging players

• Perspective Therapeutics: Perspective Therapeutics develops targeted radiopharmaceuticals for cancer, including prostate cancer. It is an emerging player in radiation-based prostate therapies that could either compete with or complement BXTA's LDR seed approach as the field moves toward targeted radionuclide therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/BXTA_
• Facebookfacebook.com/bxtainternational
• LinkedInlinkedin.com/company/bxtaccelyon

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BXTAccelyon